alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014463EN.01001501.xml

| 23.12.2014 | EN | Official Journal of the European Union | C 463/15 |
| --- | --- | --- | --- |

23.12.2014

EN

Official Journal of the European Union

C 463/15

---

Euro exchange rates (1)

1

22 December 2014

(2014/C 463/03)

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2259 |
| JPY | Japanese yen | 147,06 |
| DKK | Danish krone | 7,4401 |
| GBP | Pound sterling | 0,78490 |
| SEK | Swedish krona | 9,5536 |
| CHF | Swiss franc | 1,2035 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 9,0565 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,618 |
| HUF | Hungarian forint | 315,33 |
| LTL | Lithuanian litas | 3,45280 |
| PLN | Polish zloty | 4,2665 |
| RON | Romanian leu | 4,4666 |
| TRY | Turkish lira | 2,8423 |
| AUD | Australian dollar | 1,5057 |
| CAD | Canadian dollar | 1,4257 |
| HKD | Hong Kong dollar | 9,5098 |
| NZD | New Zealand dollar | 1,5803 |
| SGD | Singapore dollar | 1,6171 |
| KRW | South Korean won | 1 343,82 |
| ZAR | South African rand | 14,2082 |
| CNY | Chinese yuan renminbi | 7,6271 |
| HRK | Croatian kuna | 7,6650 |
| IDR | Indonesian rupiah | 15 255,54 |
| MYR | Malaysian ringgit | 4,2839 |
| PHP | Philippine peso | 54,723 |
| RUB | Russian rouble | 67,1555 |
| THB | Thai baht | 40,282 |
| BRL | Brazilian real | 3,2455 |
| MXN | Mexican peso | 17,8608 |
| INR | Indian rupee | 77,4769 |

Currency

Exchange rate

USD

US dollar

1,2259

JPY

Japanese yen

147,06

DKK

Danish krone

7,4401

GBP

Pound sterling

0,78490

SEK

Swedish krona

9,5536

CHF

Swiss franc

1,2035

ISK

Iceland króna

NOK

Norwegian krone

9,0565

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,618

HUF

Hungarian forint

315,33

LTL

Lithuanian litas

3,45280

PLN

Polish zloty

4,2665

RON

Romanian leu

4,4666

TRY

Turkish lira

2,8423

AUD

Australian dollar

1,5057

CAD

Canadian dollar

1,4257

HKD

Hong Kong dollar

9,5098

NZD

New Zealand dollar

1,5803

SGD

Singapore dollar

1,6171

KRW

South Korean won

1 343,82

ZAR

South African rand

14,2082

CNY

Chinese yuan renminbi

7,6271

HRK

Croatian kuna

7,6650

IDR

Indonesian rupiah

15 255,54

MYR

Malaysian ringgit

4,2839

PHP

Philippine peso

54,723

RUB

Russian rouble

67,1555

THB

Thai baht

40,282

BRL

Brazilian real

3,2455

MXN

Mexican peso

17,8608

INR

Indian rupee

77,4769

---

(1)  Source: reference exchange rate published by the ECB.

1

Source

---
# C_2016050EN.01000201.xml

| 10.2.2016 | EN | Official Journal of the European Union | C 50/2 |
| --- | --- | --- | --- |

10.2.2016

EN

Official Journal of the European Union

C 50/2

---

Euro exchange rates (1)

1

9 February 2016

(2016/C 50/02)

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1236 |
| JPY | Japanese yen | 129,07 |
| DKK | Danish krone | 7,4635 |
| GBP | Pound sterling | 0,77945 |
| SEK | Swedish krona | 9,5142 |
| CHF | Swiss franc | 1,0997 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 9,6705 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,058 |
| HUF | Hungarian forint | 311,55 |
| PLN | Polish zloty | 4,4530 |
| RON | Romanian leu | 4,4943 |
| TRY | Turkish lira | 3,3154 |
| AUD | Australian dollar | 1,6083 |
| CAD | Canadian dollar | 1,5623 |
| HKD | Hong Kong dollar | 8,7585 |
| NZD | New Zealand dollar | 1,7085 |
| SGD | Singapore dollar | 1,5767 |
| KRW | South Korean won | 1 356,24 |
| ZAR | South African rand | 18,1960 |
| CNY | Chinese yuan renminbi | 7,3924 |
| HRK | Croatian kuna | 7,6420 |
| IDR | Indonesian rupiah | 15 307,42 |
| MYR | Malaysian ringgit | 4,6880 |
| PHP | Philippine peso | 53,641 |
| RUB | Russian rouble | 88,3952 |
| THB | Thai baht | 39,829 |
| BRL | Brazilian real | 4,3741 |
| MXN | Mexican peso | 21,1922 |
| INR | Indian rupee | 76,4549 |

Currency

Exchange rate

USD

US dollar

1,1236

JPY

Japanese yen

129,07

DKK

Danish krone

7,4635

GBP

Pound sterling

0,77945

SEK

Swedish krona

9,5142

CHF

Swiss franc

1,0997

ISK

Iceland króna

NOK

Norwegian krone

9,6705

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,058

HUF

Hungarian forint

311,55

PLN

Polish zloty

4,4530

RON

Romanian leu

4,4943

TRY

Turkish lira

3,3154

AUD

Australian dollar

1,6083

CAD

Canadian dollar

1,5623

HKD

Hong Kong dollar

8,7585

NZD

New Zealand dollar

1,7085

SGD

Singapore dollar

1,5767

KRW

South Korean won

1 356,24

ZAR

South African rand

18,1960

CNY

Chinese yuan renminbi

7,3924

HRK

Croatian kuna

7,6420

IDR

Indonesian rupiah

15 307,42

MYR

Malaysian ringgit

4,6880

PHP

Philippine peso

53,641

RUB

Russian rouble

88,3952

THB

Thai baht

39,829

BRL

Brazilian real

4,3741

MXN

Mexican peso

21,1922

INR

Indian rupee

76,4549

---

(1)  Source: reference exchange rate published by the ECB.

1

Source

---
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA
F OURTH D ISTRICT

MARK GRUDZIELANEK , Appellant,

v.

MARK DAMERAU , Appellee

.

No. 4D 17

- 1718

[ March 29, 2018 ]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm Beach County ; Edward A. Garrison , Judge; L.T. Case No. 50

- 2016

- CA

008883

- XXXX

- MB

.
Kevin F. Richardson and Christopher J. Ryan of Clyatt, Richardson & Ryan, P.A., West Palm Beach, for appellant.

Stephanie L. Serafin and Jane Kreusler

- Walsh of Kreusler

- Walsh Vargas & Serafin, P. A., West Palm Beach; and Charles D. Thomas of Thompson & Thomas, PA, West Palm Beach, for appellee.

P ER C URIAM

.
Affirmed.

C IKLIN , C ONNER and F ORST , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
# C_2016242EN.01000501.xml

| 2.7.2016 | EN | Official Journal of the European Union | C 242/5 |
| --- | --- | --- | --- |

2.7.2016

EN

Official Journal of the European Union

C 242/5

---

Interest rate applied by the European Central Bank to its main refinancing operations (1):

1

0,00 % on 1 July 2016

Euro exchange rates (2)

2

1 July 2016

(2016/C 242/04)

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1135 |
| JPY | Japanese yen | 114,29 |
| DKK | Danish krone | 7,4380 |
| GBP | Pound sterling | 0,83830 |
| SEK | Swedish krona | 9,3900 |
| CHF | Swiss franc | 1,0835 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 9,2975 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,093 |
| HUF | Hungarian forint | 316,52 |
| PLN | Polish zloty | 4,3966 |
| RON | Romanian leu | 4,5157 |
| TRY | Turkish lira | 3,2077 |
| AUD | Australian dollar | 1,4884 |
| CAD | Canadian dollar | 1,4390 |
| HKD | Hong Kong dollar | 8,6393 |
| NZD | New Zealand dollar | 1,5508 |
| SGD | Singapore dollar | 1,4959 |
| KRW | South Korean won | 1 275,76 |
| ZAR | South African rand | 16,2287 |
| CNY | Chinese yuan renminbi | 7,4111 |
| HRK | Croatian kuna | 7,5235 |
| IDR | Indonesian rupiah | 14 597,99 |
| MYR | Malaysian ringgit | 4,4376 |
| PHP | Philippine peso | 52,334 |
| RUB | Russian rouble | 71,3087 |
| THB | Thai baht | 39,033 |
| BRL | Brazilian real | 3,5837 |
| MXN | Mexican peso | 20,1814 |
| INR | Indian rupee | 74,9698 |

Currency

Exchange rate

USD

US dollar

1,1135

JPY

Japanese yen

114,29

DKK

Danish krone

7,4380

GBP

Pound sterling

0,83830

SEK

Swedish krona

9,3900

CHF

Swiss franc

1,0835

ISK

Iceland króna

NOK

Norwegian krone

9,2975

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,093

HUF

Hungarian forint

316,52

PLN

Polish zloty

4,3966

RON

Romanian leu

4,5157

TRY

Turkish lira

3,2077

AUD

Australian dollar

1,4884

CAD

Canadian dollar

1,4390

HKD

Hong Kong dollar

8,6393

NZD

New Zealand dollar

1,5508

SGD

Singapore dollar

1,4959

KRW

South Korean won

1 275,76

ZAR

South African rand

16,2287

CNY

Chinese yuan renminbi

7,4111

HRK

Croatian kuna

7,5235

IDR

Indonesian rupiah

14 597,99

MYR

Malaysian ringgit

4,4376

PHP

Philippine peso

52,334

RUB

Russian rouble

71,3087

THB

Thai baht

39,033

BRL

Brazilian real

3,5837

MXN

Mexican peso

20,1814

INR

Indian rupee

74,9698

---

(1)  Rate applied to the most recent operation carried out before the indicated day. In the case of a variable rate tender, the interest rate is the marginal rate.

1

(2)  Source: reference exchange rate published by the ECB.

2

Source

---
Fourth Court of Appeals

San Antonio, Texas

MEMORANDUM OPINION

No. 04-20-00029-CV

TEXAS MUTUAL INSURANCE COMPANY,

Appellant

v.

VERACITY AVIATION LLC; Robinson Helicopter Company; Gillespie Air Services, Inc. 

and Gillespie Air Services, Inc. d/b/a Fredericksburg FBO; Eric A. Spitzer LLC; Gary D. 

Monroe and J. Travis Monroe, as the representative of the Estate of Chester S. Monroe; and John 

Doe, Temporary Administrator of the Estate of Chester E. Monroe,

Appellees

From the 451st Judicial District Court, Kendall County, Texas

Trial Court No. 14-472

Honorable Kirsten Cohoon, Judge Presiding

PER CURIAM

Sitting: Irene Rios, Justice

Beth Watkins, Justice

Liza A. Rodriguez, Justice

Delivered and Filed: March 25, 2020

MOTION TO DISMISS GRANTED; DISMISSED

Appellant has filed a motion to dismiss this appeal. The motion contains a certificate of 

service to appellees, who have not opposed the motion. Therefore, we grant the motion and dismiss 

the appeal. See TEX. R. APP. P. 42.1(a). However, costs of appeal are taxed against appellant. See 

id. 42.1(d) (requiring court to assess costs against the appellant absent agreement of the parties).

PER CURIAM
Hennion & Walsh, Inc. 487


Exhibit 4.3


 



 


 


Consent of Independent Registered Public
Accounting Firm


We have issued our report
dated October 13, 2021, with respect to the financial statement of SmartTrust 537 contained in Amendment No. 1 to the Registration Statement
on Form S-6 (File No. 333-258217) and related Prospectus. We consent to the use of the aforementioned report in the Registration Statement
and Prospectus, and to the use of our name as it appears under the caption “Independent Registered Public Accounting Firm”.


 


/s/ Grant
Thornton LLP


 


Chicago, Illinois


October 13, 2021
EXHIBIT
      32.1


**CERTIFICATION
        PURSUANT TO**
 **18
        U.S.C. SECTION 1350,**
 **AS
        ADOPTED PURSUANT TO**
 **SECTION
        906 OF THE SARBANES-OXLEY ACT OF 2002**
  In
        connection
        with the Quarterly Report of Sangui BioTech International, Inc. (the “Company”)
        on Form 10-QSB for the period ending March 31, 2006 as filed with the
        Securities and Exchange Commission on the date hereof (the “Report”), I,
        Wolfgang Barnikol, Chief Executive Officer and Chief Financial Officer of
        the
        Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to
§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge
        and belief:
  (1)        The
        Report fully complies with the requirements of section 13(a) or 15(d) of
        the Securities Exchange Act of 1934; and
  (2)        The
        information contained in the Report fairly presents, in all material respects,
        the financial condition and result of operations of the Company.
   Date:
              November 30,
              2007                             /s/  Wolfgang
              Barnikol
 By:
            Wolfgang Barnikol
 Chief
            Executive Officer and Chief Financial Officer
   A
        signed
        original of this written statement required by Section 906, or other document
        authenticating, acknowledging, or otherwise adopting the signature that appears
        in typed form within the electronic version of this written statement has
        been
        provided to the Company and will be retained by the Company and furnished
        to the
        Securities and Exchange Commission or its staff upon request.
##### 



Exhibit 12
 Mariner Energy, Inc.
 Ratio of Earnings to Fixed Charges
(Unaudited)
 For the Years EndedDecember 31,
    
    
    December 31,
    
    
    December 31,
    
    
    December 31,
    
    
    December 31,(In thousands, except ratio)
    
    2006
    
    
    2005
    
    
    2004
    
    
    2003
    
    
    2002Earnings from continuing
operations before fixed
chargesIncome before taxes
    
    
    188,806
    
    
    
    61,775
    
    
    
    105,300
    
    
    
    45,688
    
    
    
    29,993Add: Fixed charges less
capitalized interest
    
    
    38,664
    
    
    
    8,172
    
    
    
    6,050
    
    
    
    6,981
    
    
    
    10,298Earnings from continuing
operations before fixed
charges
    
    
    227,470
    
    
    
    69,947
    
    
    
    111,350
    
    
    
    52,669
    
    
    
    40,291Fixed ChargesInterest expense, net of
capitalized interest
    
    
    38,275
    
    
    
    8,172
    
    
    
    6,050
    
    
    
    6,981
    
    
    
    10,298Add: Capitalized interest
    
    
    1,528
    
    
    
    703
    
    
    
    434
    
    
    
    727
    
    
    
    1,021Add: Amortization of discounts
    
    
    389
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Total Fixed Charges
    
    
    40,192
    
    
    
    8,875
    
    
    
    6,484
    
    
    
    7,708
    
    
    
    11,319Ratio of earnings to fixed
charges
    
    
    5.66
    
    
    
    7.88
    
    
    
    17.17
    
    
    
    6.83
    
    
    
    3.56
# C_2015301EN.01000902.xml

| 12.9.2015 | EN | Official Journal of the European Union | C 301/9 |
| --- | --- | --- | --- |

12.9.2015

EN

Official Journal of the European Union

C 301/9

---

Non-opposition to a notified concentration

(Case M.7685 — Perrigo/GSK Divestment Businesses)

(Text with EEA relevance)

(2015/C 301/03)

On 21 August 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in the English language and will be made public after it is cleared of any business secrets it may contain. It will be available:

1

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7685. EUR-Lex is the online access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7685. EUR-Lex is the online access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---
CERTIFICATIONS

I, Jay Sargeant, Chief Executive Officer of EYI Industries, Inc. (the
"Registrant"), certify that;

(1)   I have reviewed this Quarterly Report on Form 10-QSB of EYI Industries,
      Inc.;

(2)   Based on my knowledge, this report does not contain any untrue statement
      of a material fact or omit to state a material fact necessary to make the
      statements made, in light of the circumstances under which such statements
      were made, not misleading with respect to the period covered by this
      report;

(3)   Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the Registrant as of, and for, the periods presented in this report;

(4)   The Registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant
      and have:

      a)    Designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            Registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this report is being prepared;

      b)    Evaluated the effectiveness of the Registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures, as of
            the end of the period covered by this report based on such
            evaluation; and

      c)    Disclosed in this report any change in the Registrant's internal
            control over financial reporting that occurred during the
            Registrant's most recent fiscal quarter that has materially
            affected, or is reasonably likely to materially affect, the
            Registrant's internal control over financial reporting; and

(5)   The Registrant's other certifying officer(s) and I have disclosed, based
      on our most recent evaluation of the internal control over financial
      reporting, to the Registrant's auditors and the audit committee of
      Registrant's board of directors (or persons performing the equivalent
      functions):

      a)    All significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect the Registrant's ability to
            record, process, summarize and report financial information; and

      b)    Any fraud, whether or not material, that involves management or
            other employees who have a significant role in the Registrant's
            internal control over financial reporting.

Date:      August 19, 2005


         /s/ Jay Sargeant
By:      Jay Sargeant
Title:   Chief Executive Officer
EXHIBIT 32.1

                            SECTION 906 CERTIFICATION






<PAGE>
                                  Exhibit 32.1

                     CERTIFICATION OF DISCLOSURE PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of ASPI,  Inc. (the "Company") on Form
10-K for the year ended June 30, 2011 as filed with the  Securities and Exchange
Commission  on the date  hereof  (the  "Report")  I, Look Yuen  Ling,  Principal
Executive Officer,  President,  Chief Executive Officer and Principal  Financial
Officer and Chief Financial Officer of the Company,  certify, pursuant to 18 USC
section 1350, as adopted  pursuant to section 906 of the  Sarbanes-Oxley  Act of
2002, that to the best of my knowledge and belief:

         (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.


Dated:  October 12, 2011

Name: Look Yuen Ling

/s/ Look Yuen Ling
--------------------------------------------------------------------------------
Look Yuen Ling, (Principal Executive & Financial Officer,
President, Chief Executive Officer and Chief Financial Officer)


This  certification  accompanies  the  Report  pursuant  to  Section  906 of the
Sarbanes-Oxley  Act of 2002 and shall not,  except to the extent required by the
Sarbanes-Oxley  Act of 2002,  be deemed  filed by the  Company  for  purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.
Exhibit 32.01  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In connection with the Quarterly Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the period ending December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Striepe, Chief Executive Officer and I, Joachim Fleing, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.    Dated: October 3, 2011 /s/ Thomas Striepe By: Thomas Striepe Chief Executive Officer   Dated: October 3, 2011 /s/ Joachim Fleing By: Joachim Fleing Chief Financial Officer   A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Order entered December 2, 2016

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-14-00856-CV

IN THE INTEREST OF C.S.B AND R.D.B, Children

On Appeal from the 255th Judicial District Court

Dallas County, Texas

Trial Court Cause No. DF-11-15158

ORDER

I hereby voluntarily recuse myself from hearing any matter in the above appeal.

/s/ ADA BROWN 

JUSTICE
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 16-1670

In Re: BRETT C. KIMBERLIN,

Petitioner.

On Petition for Writ of Mandamus. 

(8:13-cv-03059-GJH)

Submitted: November 10, 2016 Decided: December 7, 2016

Before WILKINSON and HARRIS, Circuit Judges, and HAMILTON, 

Senior Circuit Judge.

Petition denied by unpublished per curiam opinion.

Brett C. Kimberlin, Petitioner Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Brett C. Kimberlin petitions for a writ of mandamus seeking 

an order directing the district court to vacate its protective 

order covering pretrial discovery and to allow him to publicly 

use discovery documents marked confidential that have not yet 

been filed in court. Mandamus relief is a drastic remedy and 

should be used only in extraordinary circumstances. Kerr v. 

U.S. Dist. Court, 426 U.S. 394, 402 (1976); United States v. 

Moussaoui, 333 F.3d 509, 516-17 (4th Cir. 2003). The party 

seeking issuance of the writ must have no other adequate means 

to attain relief, and he bears the burden of showing that his 

right to the writ is clear and indisputable. Moussaoui, 333 

F.3d at 517 (citations omitted). We have reviewed the petition 

and conclude that Kimberlin fails to make this showing.

Accordingly, we deny the petition for a writ of mandamus. 

We deny the motion to expedite as moot. We dispense with oral 

argument because the facts and legal contentions are adequately 

presented in the materials before this court and argument would 

not aid the decisional process.

PETITION DENIED